Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prognostic Factors for Visual Improvement with Ranibizumab in RVO
NCT02144662Completed
- Sponsor
- St. Marianna University School of Medicine
- Start
- Mar 2014
- Primary completion
- Jan 2017
- Modality
- Antibody Fragments, Antibody Conjugates, Monoclonal Antibodies
01
Overview
Open-label, single-arm trial of ranibizumab in retinal vein occlusion (RVO), sponsored by St. Marianna University School of Medicine. Primary endpoint: Best-corrected visual acuity at 1 year. Started Mar 2014; status: completed.
02
Drugs
ranibizumab
03
Conditions
retinal vein occlusion (RVO)
Beyond the preview
Go deeper on NCT02144662.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02144662.